Chronic rhinosinusitis with nasal polyps (CRSwNP) and Severe Eosinophilic Asthma (SEA) are both frequently sustained by eosinophilic inflammation and are probably the manifestation of a unique disease of upper and lower respiratory tract. We retrospectively observed 11 patients with severe CRSwNP and concomitant SEA under add-on therapy with benralizumab evaluating symptoms using Sino Nasal Outcome Test-22 (SNOT-22), Visual Analogue Scale (VAS), and Asthma Control Test (ACT) and Nasal polyp size by endoscopic and radiological score by Nasal Polyp Score (NPS) and Lund-Mackay Score (LMS). At 6 and 12 months, the expression of cationic eosinophil protein (ECP), Interleukin 17 (IL-17), Interferon gamma (INF-γ), and vascular endothelial growth factor (VEGF) was measured by nasal scraping to assess mucosal inflammation. After 12 months of benralizumab treatment, SNOT-22 decreased from 45 (23–97) to 14 (5–53) (p < 0.05), total VAS of rhinologic symptoms decreased from 30 (17–44) to 9 (5–37) (p ≤ 0.01) and ACT score increased from 10 (5–15) to 24 (20–25) (p ≤ 0.01). NPS decreased from 5 (3–6) to 3 (2–4) after 6 months (p < 0.05) and to 2 (2–3) after one year respectively (p < 0.05) and LMS total score from 21 (15–24) to 17 (8–21) (p ≤ 0.01) after 12 months from starting treatment. Nasal mucosa scraping found differences in INF-γ and VEGF expression in patients compared to 10 healthy subjects, with a normalization of these markers during eosinophils depletion induced by benralizumab. This is the first pilot real-life study conducted with an anti-IL5R monoclonal antibody in severe eosinophilic asthma and severe CRSwNP patients showing that this treatment can induce benefit both diseases not only from the clinical, but also from the inflammatory point of view. Moreover, our research pointed out that INF-γ and VEGF may represent potential response biomarker.

Benralizumab reduces eosinophils and inflammatory markers in patients with severe eosinophilic asthma and chronic rhinosinusitis with nasal polyps: a pilot real-life study / Cavaliere, Carlo; Segatto, Marco; Ciofalo, Andrea; Colizza, Andrea; Minni, Antonio; Messineo, Daniela; Lambiase, Alessandro; Greco, Antonio; De Vincentiis, Marco; Masieri, Simonetta. - In: IMMUNOLOGY LETTERS. - ISSN 0165-2478. - 248:(2022), pp. 70-77. [10.1016/j.imlet.2022.06.009]

Benralizumab reduces eosinophils and inflammatory markers in patients with severe eosinophilic asthma and chronic rhinosinusitis with nasal polyps: a pilot real-life study

Carlo Cavaliere
Primo
;
Andrea Ciofalo;Andrea Colizza;Antonio Minni;Daniela Messineo;Alessandro Lambiase;Antonio Greco;Marco de Vincentiis
Penultimo
;
Simonetta Masieri
Ultimo
2022

Abstract

Chronic rhinosinusitis with nasal polyps (CRSwNP) and Severe Eosinophilic Asthma (SEA) are both frequently sustained by eosinophilic inflammation and are probably the manifestation of a unique disease of upper and lower respiratory tract. We retrospectively observed 11 patients with severe CRSwNP and concomitant SEA under add-on therapy with benralizumab evaluating symptoms using Sino Nasal Outcome Test-22 (SNOT-22), Visual Analogue Scale (VAS), and Asthma Control Test (ACT) and Nasal polyp size by endoscopic and radiological score by Nasal Polyp Score (NPS) and Lund-Mackay Score (LMS). At 6 and 12 months, the expression of cationic eosinophil protein (ECP), Interleukin 17 (IL-17), Interferon gamma (INF-γ), and vascular endothelial growth factor (VEGF) was measured by nasal scraping to assess mucosal inflammation. After 12 months of benralizumab treatment, SNOT-22 decreased from 45 (23–97) to 14 (5–53) (p < 0.05), total VAS of rhinologic symptoms decreased from 30 (17–44) to 9 (5–37) (p ≤ 0.01) and ACT score increased from 10 (5–15) to 24 (20–25) (p ≤ 0.01). NPS decreased from 5 (3–6) to 3 (2–4) after 6 months (p < 0.05) and to 2 (2–3) after one year respectively (p < 0.05) and LMS total score from 21 (15–24) to 17 (8–21) (p ≤ 0.01) after 12 months from starting treatment. Nasal mucosa scraping found differences in INF-γ and VEGF expression in patients compared to 10 healthy subjects, with a normalization of these markers during eosinophils depletion induced by benralizumab. This is the first pilot real-life study conducted with an anti-IL5R monoclonal antibody in severe eosinophilic asthma and severe CRSwNP patients showing that this treatment can induce benefit both diseases not only from the clinical, but also from the inflammatory point of view. Moreover, our research pointed out that INF-γ and VEGF may represent potential response biomarker.
File allegati a questo prodotto
File Dimensione Formato  
Cavaliere_Benralizumab reduces_2022.pdf

accesso aperto

Note: https://www.sciencedirect.com/science/article/pii/S0165247822000967?via=ihub
Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 2.44 MB
Formato Adobe PDF
2.44 MB Adobe PDF Visualizza/Apri PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1649367
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 0
social impact